Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data

Emmanuel Disse, Judith Aron-Wisnewsky, David Jacobi, Karine Clément, Martine Laville, Cyril Gauthier, François Pattou, Julie Molleville, Melissa Akerib, Lysiane Jubin, Blandine Gatta-Cherifi, Bénédicte Gaborit, Emilie Montastier, Fabien Stenard, Claire Carette, Najate Achamrah, Antoine Avignon, Sébastien Czernichow, Camille Sollier, Bérénice Segrestin, Anne Dutour, Jean-Baptiste Bonnet, Charles Barsamian, Pierre Belassen, Diana Shenouda, Ana Estrade, Alain Pradignac, Vanessa Folope, Najate Achamrah, Naima Oukhouyadaoud, Rudy Caillet, Mohamed Zerguine, Marie-Claude Brindisi, Séverine Ledoux, Maud Monsaingeon-Henry, Agnès Sallé, Magalie Miolanne, Mickael Som, Séverine Andrieux, Marion Bretault, Anne-Cécile Paepegaey, Yann Matussiere, Anne-Laure Sberna, Geraldine Vitellius, Syrine Jarraya, Nicolas Chevalier, Véronique Taillard, Anca Montagnier, Marie Guillouche, Géraldine Lévy, Pauline Suzeau, Alexandre Schwanke, Héléna Mosbah, Geoffroy Boulate, Said Bekka, Laurène Bosc, Ibrahim Hamadeh, Thomas Leroi, Virginie Castera, Frédérique Olivier, Vincent Appavoupoulle, Alexandre Jehl, Océane Lheveder, Marie-Laure Lalanne-Mistrih, Audrey Lamoliate, Patricia Degrelle, Jean-Sébastien Lanne, Nadia Sabbah, Elias Barrak, Lise Pagniez, Salvatore Avallone, Dominique Boute, Lyse Bordier

Open source

DOI
10.1016/j.diabet.2025.101625
Published
2025-05
Container
Diabetes & Metabolism
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.diabet.2025.101625,
  title = {Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data},
  author = {Emmanuel Disse and Judith Aron-Wisnewsky and David Jacobi and Karine Clément and Martine Laville and Cyril Gauthier and François Pattou and Julie Molleville and Melissa Akerib and Lysiane Jubin and Blandine Gatta-Cherifi and Bénédicte Gaborit and Emilie Montastier and Fabien Stenard and Claire Carette and Najate Achamrah and Antoine Avignon and Sébastien Czernichow and Camille Sollier and Bérénice Segrestin and Anne Dutour and Jean-Baptiste Bonnet and Charles Barsamian and Pierre Belassen and Diana Shenouda and Ana Estrade and Alain Pradignac and Vanessa Folope and Najate Achamrah and Naima Oukhouyadaoud and Rudy Caillet and Mohamed Zerguine and Marie-Claude Brindisi and Séverine Ledoux and Maud Monsaingeon-Henry and Agnès Sallé and Magalie Miolanne and Mickael Som and Séverine Andrieux and Marion Bretault and Anne-Cécile Paepegaey and Yann Matussiere and Anne-Laure Sberna and Geraldine Vitellius and Syrine Jarraya and Nicolas Chevalier and Véronique Taillard and Anca Montagnier and Marie Guillouche and Géraldine Lévy and Pauline Suzeau and Alexandre Schwanke and Héléna Mosbah and Geoffroy Boulate and Said Bekka and Laurène Bosc and Ibrahim Hamadeh and Thomas Leroi and Virginie Castera and Frédérique Olivier and Vincent Appavoupoulle and Alexandre Jehl and Océane Lheveder and Marie-Laure Lalanne-Mistrih and Audrey Lamoliate and Patricia Degrelle and Jean-Sébastien Lanne and Nadia Sabbah and Elias Barrak and Lise Pagniez and Salvatore Avallone and Dominique Boute and Lyse Bordier},
  year = {2025},
  journal = {Diabetes \& Metabolism},
  doi = {10.1016/j.diabet.2025.101625},
  url = {https://doi.org/10.1016/j.diabet.2025.101625}
}

RIS

TY  - JOUR
TI  - Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data
AU  - Emmanuel Disse
AU  - Judith Aron-Wisnewsky
AU  - David Jacobi
AU  - Karine Clément
AU  - Martine Laville
AU  - Cyril Gauthier
AU  - François Pattou
AU  - Julie Molleville
AU  - Melissa Akerib
AU  - Lysiane Jubin
AU  - Blandine Gatta-Cherifi
AU  - Bénédicte Gaborit
AU  - Emilie Montastier
AU  - Fabien Stenard
AU  - Claire Carette
AU  - Najate Achamrah
AU  - Antoine Avignon
AU  - Sébastien Czernichow
AU  - Camille Sollier
AU  - Bérénice Segrestin
AU  - Anne Dutour
AU  - Jean-Baptiste Bonnet
AU  - Charles Barsamian
AU  - Pierre Belassen
AU  - Diana Shenouda
AU  - Ana Estrade
AU  - Alain Pradignac
AU  - Vanessa Folope
AU  - Najate Achamrah
AU  - Naima Oukhouyadaoud
AU  - Rudy Caillet
AU  - Mohamed Zerguine
AU  - Marie-Claude Brindisi
AU  - Séverine Ledoux
AU  - Maud Monsaingeon-Henry
AU  - Agnès Sallé
AU  - Magalie Miolanne
AU  - Mickael Som
AU  - Séverine Andrieux
AU  - Marion Bretault
AU  - Anne-Cécile Paepegaey
AU  - Yann Matussiere
AU  - Anne-Laure Sberna
AU  - Geraldine Vitellius
AU  - Syrine Jarraya
AU  - Nicolas Chevalier
AU  - Véronique Taillard
AU  - Anca Montagnier
AU  - Marie Guillouche
AU  - Géraldine Lévy
AU  - Pauline Suzeau
AU  - Alexandre Schwanke
AU  - Héléna Mosbah
AU  - Geoffroy Boulate
AU  - Said Bekka
AU  - Laurène Bosc
AU  - Ibrahim Hamadeh
AU  - Thomas Leroi
AU  - Virginie Castera
AU  - Frédérique Olivier
AU  - Vincent Appavoupoulle
AU  - Alexandre Jehl
AU  - Océane Lheveder
AU  - Marie-Laure Lalanne-Mistrih
AU  - Audrey Lamoliate
AU  - Patricia Degrelle
AU  - Jean-Sébastien Lanne
AU  - Nadia Sabbah
AU  - Elias Barrak
AU  - Lise Pagniez
AU  - Salvatore Avallone
AU  - Dominique Boute
AU  - Lyse Bordier
PY  - 2025
JO  - Diabetes & Metabolism
DO  - 10.1016/j.diabet.2025.101625
UR  - https://doi.org/10.1016/j.diabet.2025.101625
ER  -

APA

Disse, E., Aron-Wisnewsky, J., Jacobi, D., Clément, K., Laville, M., Gauthier, C., Pattou, F., Molleville, J., Akerib, M., Jubin, L., Gatta-Cherifi, B., Gaborit, B., Montastier, E., Stenard, F., Carette, C., Achamrah, N., Avignon, A., Czernichow, S., Sollier, C., Segrestin, B., Dutour, A., Bonnet, J., Barsamian, C., Belassen, P., Shenouda, D., Estrade, A., Pradignac, A., Folope, V., Achamrah, N., Oukhouyadaoud, N., Caillet, R., Zerguine, M., Brindisi, M., Ledoux, S., Monsaingeon-Henry, M., Sallé, A., Miolanne, M., Som, M., Andrieux, S., Bretault, M., Paepegaey, A., Matussiere, Y., Sberna, A., Vitellius, G., Jarraya, S., Chevalier, N., Taillard, V., Montagnier, A., Guillouche, M., Lévy, G., Suzeau, P., Schwanke, A., Mosbah, H., Boulate, G., Bekka, S., Bosc, L., Hamadeh, I., Leroi, T., Castera, V., Olivier, F., Appavoupoulle, V., Jehl, A., Lheveder, O., Lalanne-Mistrih, M., Lamoliate, A., Degrelle, P., Lanne, J., Sabbah, N., Barrak, E., Pagniez, L., Avallone, S., Boute, D., & Bordier, L. (2025). Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data. Diabetes & Metabolism. https://doi.org/10.1016/j.diabet.2025.101625

Source records